Table 1. Background characteristics.
| All N = 104 | Overweight N = 29 | Non-overweight N = 75 | P (Overweight vs Non-overweight) | |
|---|---|---|---|---|
| Age | 58 ± 14 | 60 ± 14 | 58 ± 14 | 0.40 |
| Sex | 0.005 | |||
| Male sex, N (%) | 49 (47) | 20 (69) | 29 (39) | |
| Female sex, N (%) | 55 (53) | 9 (31) | 46 (61) | |
| Clinical diagnosis | 0.174 | |||
| Non-functioning adenoma | 85 (82) | 26 (90) | 59 (79) | |
| Rathke’s cyst | 19 (18) | 3 (10) | 16 (21) | |
| Pathological diagnosis, N (%) | 0.138 | |||
| Gonadotroph adenoma | 33 (32) | 7 (24) | 26 (35) | |
| Null cell adenoma | 22 (21) | 11 (38) | 11 (15) | |
| Rathke’s cyst | 11 (11) | 3 (10) | 8 (11) | |
| Others | 5 (5) | 1 (3) | 4 (5) | |
| Not pathologically diagnosed | 33 (32) | 7 (24) | 26 (35) | |
| Height, cm | 161.7 ± 9.0 | 163.4 ± 9.7 | 161.0 ± 8.7 | 0.21 |
| Body weight, kg | 62.2 ± 12.3 | 73.9 ± 11.3 | 57.6 ± 9.3 | < 0.001 |
| BMI, kg/m2 | 23.6 ± 3.2 | 27.5 ± 2.2 | 22.1 ± 2.1 | < 0.001 |
| BMI categories | < 0.001 | |||
| BMI < 25 kg/m2, N (%) | 75 (72) | 0 (0) | 75 (0) | |
| 25 kg/m2 ≤ BMI < 30 kg/m2, N (%) | 26 (25) | 26 (90) | 0 (0) | |
| BMI ≥ 30 kg/m2, N (%) | 3 (3) | 3 (10) | 0 (0) | |
| Hypertension, N (%) | 44 (42) | 21 (72) | 23 (31) | < 0.001 |
| Diabetes mellitus, N (%) | 15 (14) | 8 (28) | 7 (9) | 0.024 |
| History of smoking, N (%) | 47 (45) | 17 (59) | 30 (40) | 0.087 |
| Serum creatinine, mg/dL | 0.75 ± 0.16 | 0.80 ± 0.15 | 0.73 ± 0.16 | 0.025 |
| Estimated GFR, mL/min/1.73 m2 | 74.5 ± 14.3 | 71.7 ± 10.8 | 75.6 ± 15.4 | 0.22 |
| CKD categories | 0.101 | |||
| 30 mL/min/1.73 m2 < estimated GFR ≤ 60 mL/min/1.73 m2, N (%) | 17 (16) | 4 (14) | 13 (17) | |
| 60 mL/min/1.73 m2 ≤ estimated GFR < 90 mL/min/1.73 m2, N (%) | 72 (69) | 24 (83) | 48 (64) | |
| Estimated GFR ≥ 90 mL/min/1.73 m2, N (%) | 15 (14) | 1 (3) | 14 (19) | |
| Hemoglobin A1c, % | 5.7 (5.5–6.1) | 5.8 (5.6–6.4) | 5.7 (5.4–6.0) | 0.030 |
| Peak GH after GHRP-2 injection, ng/mL | 13.63 (3.22–26.82) | 3.40 (1.30–15.92) | 15.39 (4.64–34.64) | 0.001 |
| Severe GH deficiency (peak GH < 9 ng/mL), N (%) | 45 (43) | 19 (66) | 26 (35) | 0.004 |
| IGF-1, ng/mL | 96 (74–127) | 90 (59–118) | 102(80–128) | 0.172 |
| IGF-1 SD score | -1.1 ± 1.3 | -1.2 ± 1.5 | -1.0 ± 1.3 | 0.41 |
| Free thyroxine, ng/dL | 1.11 ± 0.24 | 1.04 ± 0.25 | 1.14 ± 0.23 | 0.064 |
| Urinary albumin to creatinine ratio, mg/gCr | 4.8 (3.1–10.7) | 4.9 (3.6–18.6) | 4.5 (2.8–8.9) | 0.29 |
| Tumor size | ||||
| Width, mm | 20.8 ± 8.3 | 20.3 ± 7.7 | 20.9 ± 8.5 | 0.72 |
| Height, mm | 20.0 ± 9.3 | 19.9 ± 9.0 | 20.1 ± 9.5 | 0.94 |
| Depth, mm | 16.9 ± 7.2 | 17.1 ± 7.1 | 16.8 ± 7.3 | 0.83 |
Data are presented as mean ± SD or median (interquartile range [IQR]). BMI, body mass index; GFR, glomerular filtration rate; CKD, chronic kidney disease; GH, growth hormone; GHRP-2, growth hormone-releasing peptide-2; SD, standard deviation.